HLB Therapeutics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
HLB Therapeutics is a South Korean company listed on KOSDAQ that operates across three business lines: biopharmaceutical drug development, cold-chain logistics and pharmaceutical distribution, and electronics components such as motors and pumps.
Its biopharmaceutical work involves developing new drugs, with clinical programs run through US-based subsidiaries, while its distribution arm supplies medicines through domestic channels. The company is actively restructuring toward a bio-focused business, having spun off its electronics operations into a wholly owned subsidiary.
Summary is AI-generated and may contain errors · figures from DART filings
The electronics division was separated into a newly established wholly owned subsidiary, Core Industries Co., Ltd., through a physical spin-off approved at an extraordinary shareholders' meeting.
HLB Therapeutics in five facts
What does HLB Therapeutics do?
HLB Therapeutics is a South Korean company listed on KOSDAQ that operates across three business lines: biopharmaceutical drug development, cold-chain logistics and pharmaceutical distribution, and electronics components such as motors and pumps.
Where is HLB Therapeutics listed and in which sector?
HLB Therapeutics (Korean name: HLB테라퓨틱스) trades under KRX code 115450 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Trading & Distribution.
How large is HLB Therapeutics?
Its market capitalisation was US$193.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were HLB Therapeutics's latest annual revenue and operating profit?
For fiscal year 2025, HLB Therapeutics reported revenue of US$52.5M, an operating loss of US$2.7M and a net loss of US$7.3M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 26.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 21
- Investor relations (IR) meetingOct 12
- Report on large shareholdings (5% rule) (standard)Oct 2
- [Amended] Conversion price adjustmentSep 9
- Conversion price adjustmentSep 4
- Report on large shareholdings (5% rule) (standard)Sep 4
- Report on securities held by executives/major shareholdersSep 4
- Securities issuance results (voluntary)Aug 31
- [Amended] Supply contract signed
HLB Therapeutics updated a previously disclosed supply contract with the Public Procurement Service, now worth US$2.78M, about 6.91% of its recent annual revenue, running through Aug 2026.
Supply contract · Aug 31 - [Amended] Early redemption of convertible bonds (incl. overseas CBs)
HLB Therapeutics amended its August 6, 2026 report on the early redemption of its 17th-series convertible bonds, revising the acquisition amount from US$4,390,526 to US$4,393,120 and the acquisition date from August 20 to August 31, 2026, by agreement with the bondholder; the full US$4.31M face value will be offset via debt-to-equity conversion and the bonds cancelled.
Capital raise · Aug 21 · 2 versions - [Amended] Material event report (decision to redeem own convertible bonds early)
HLB Therapeutics Inc. amended its August 7, 2026 report on the early acquisition of its 18th-series convertible bonds, revising the acquisition amount from US$3,648,815 to US$3,650,279 and the payment date from August 20, 2026 to August 31, 2026; the US$3.6M face-value bonds, issued February 28, 2025, are being bought back in full from largest shareholder HLB Co., Ltd. following the bondholder's exercise of its put option.
Capital raise · Aug 21 · 2 versions - [Amended] Material event report (rights offering)
HLB Therapeutics updated the terms of convertible bonds to raise US$8.04M, about 4.2% of its market value.
Capital raise · Aug 21 · 2 versions - [Amended] Material event report (convertible bonds)
HLB Therapeutics updated the terms of convertible bonds to raise US$4.31M, about 2.2% of its market value.
Capital raise · Aug 21 - [Amended] Material event report (convertible bonds)
HLB Therapeutics updated the terms of convertible bonds to raise US$3.6M, about 1.9% of its market value.
Capital raise · Aug 21 - [Amended] Material event report (convertible bonds)
HLB Therapeutics updated the terms of convertible bonds to raise US$3.52M, about 1.9% of its market value.
Capital raise · Aug 7 - [Amended] Material event report (convertible bonds)
HLB Therapeutics updated the terms of convertible bonds to raise US$4.22M, about 2.2% of its market value.
Capital raise · Aug 7 - [Amended] Supply contract signed
HLB Therapeutics updated a previously disclosed supply contract with the Public Procurement Service, now worth US$2.59M, about 7.29% of its recent annual revenue.
Supply contract · Jun 30 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 1
- Ex-rights (bonus issue)Capital raise · Mar 11
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
HLB Therapeutics reported consolidated results for FY2025: revenue of US$48.9M (+26.91% year on year), an operating loss of US$2.07M and a net loss of US$5.53M.
Earnings · Feb 26 - Material event report (bonus issue)Capital raise · Feb 26
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jan 2